SCHEDULE: Foresite Capital Maintains 6.3% Stake in CASI Pharma

Foresite Capital Fund VI LP, Foresite Capital Management VI LLC, and James Tananbaum collectively report a 6.3% beneficial ownership in CASI Pharmaceuticals, Inc. Ordinary Shares.

Summary

• Foresite Capital Fund VI LP, Foresite Capital Management VI LLC, and James Tananbaum (collectively, the "Reporting Persons") filed an Amendment No. 2 to Schedule 13G.
• The Reporting Persons beneficially own 979,956 Ordinary Shares of CASI Pharmaceuticals, Inc.
• This ownership represents 6.3% of the Issuer's outstanding Ordinary Shares.
• The percentage is calculated based on 15,492,681 Ordinary Shares outstanding as of March 31, 2025, as reported in CASI Pharmaceuticals' Form 6-K filed on May 16, 2025.
• Foresite Capital Fund VI LP directly owns the shares, while Foresite Capital Management VI LLC (its general partner) and James Tananbaum (managing member of the general partner) may be deemed to have sole voting and dispositive power over these shares.

Sentiment

Score: 6

Explanation: The filing is a neutral disclosure of beneficial ownership. The continued significant stake by an institutional investor like Foresite Capital can be seen as a moderately positive signal of confidence in CASI Pharmaceuticals, but the filing itself does not contain performance data or forward-looking statements.

Positives

• Continued significant institutional ownership by Foresite Capital, indicating ongoing investor confidence in CASI Pharmaceuticals.
• Foresite Capital, a Delaware-based entity, maintains sole voting and dispositive power over its 6.3% stake, suggesting a clear and controlled investment strategy.

Future Outlook

NA

Industry Context

Foresite Capital is a prominent healthcare and life sciences investment firm. Their continued significant stake in CASI Pharmaceuticals, a biopharmaceutical company, aligns with their specialized focus on the sector. Such institutional holdings are common in the biotech industry, where long-term investment in drug development and commercialization is typical, often signaling a belief in the company's future potential.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Management: Awareness of a significant institutional holder may influence strategic decisions and communication.

Key Dates

Keywords

CASI Pharmaceuticals, Foresite Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Ordinary Shares, Biotechnology, Pharmaceuticals, SEC Filing, Investment